Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults (Q24188221)

5

0 references

author name string

Denise Küster

1

0 references

Phyllis I Spuls

2

0 references

Carsten Flohr

3

0 references

Catherine Smith

4

0 references

Stefanie Deckert

6

0 references

Thomas Schwennesen

7

0 references

Evelien Roekevisch

8

0 references

Jochen Schmitt

Cochrane Database of Systematic Reviews

9

0 references

publication date

14 November 2015

0 references

published in

0 references

cites work

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

An update on methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Health industry practices that create conflicts of interest: a policy proposal for academic medical centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

The burden of atopic dermatitis: impact on the patient, family, and society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Measuring atopic eczema severity visually: which variables are most important to patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Epidemiology of atopic dermatitis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

New insights into the epidemiology of childhood atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Management of difficult and severe eczema in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

The multifunctional role of filaggrin in allergic skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Filaggrin in the frontline: role in skin barrier function and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Systemic treatment of severe atopic eczema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

What are the best outcome measurements for atopic eczema? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

A randomized trial of methotrexate versus azathioprine for severe atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Bias in the evaluation of conflict of interest policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Systemic therapy for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Systemic therapy of childhood atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Sleepless in America: inadequate sleep and relationships to health and well-being of our nation's children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Atopic dermatitis and the atopic march

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Clinical practice. Atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

7 January 2021

Immunosuppressive agents in dermatology. An update

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

7 January 2021

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

7 January 2021

Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011939

7 January 2021